Chong Kun Dang and Hanmi to take leads in patent challenges

Published: 2015-09-25 13:49:10

Updated: 2015-09-25 13:49:10

Chong Kun Dang and Hanmi Pharm have taken leads of other domestic pharmaceutical companies not only business competition, but patent challenges which is a starting point of generic development.

Chong Kun Dang and Hanmi Pharm have tried to preoccupy the market as first generics as successful in exclusively avoiding patents of Iressa, Avodart and Futhanas and patents of Spiriva and Iressa respec...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.